{"entity":{"id":"nct06385925","kind":"trial","name":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","aka":[],"tldr":"A phase 1/2 trial of TSN1611 in advanced solid tumours, run by Tyligand Pharmaceuticals (Suzhou) Limited, now recruiting.","summary":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT06385925 by Tyligand Pharmaceuticals (Suzhou) Limited, with 440 participants planned, started 2024-04-29 and due to reach its primary completion in 2026-10-30. Interventions recorded: TSN1611.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06385925","url":"https://clinicaltrials.gov/study/NCT06385925"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06385925","phase":"1/2","setting":"Phase 1/2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation","sponsor":"Tyligand Pharmaceuticals (Suzhou) Limited","enrolled":440,"outcomes":[]},"route":"/trials/nct06385925/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}